Q32 Bio to Participate in Upcoming September Investor Conferences
Ben Wolff and Trevor Thatcher will join a Jefferies fireside chat and 1:1 meetings as Palladyne AI seeks investor attention for its embodied AI platform.
- Multiple companies, including Palladyne AI, BridgeBio, and Q32 Bio, announced plans to participate in major investor conferences throughout September 2026 to discuss clinical progress and corporate strategies.
- These leadership teams aim to engage with institutional investors through fireside chats and one-on-one meetings to detail development pipelines and proprietary technology platforms.
- Palladyne AI CEO Ben Wolff and CFO Trevor Thatcher will present at the Jefferies Global Industrials Conference on September 9, followed by the Lake Street BIG10 conference on September 10.
- Investors can access live audio webcasts for most presentations via company websites, with archived replays available for approximately 30 days following each event.
- Beyond the September schedule, IDEAYA Biosciences will host an Investor R&D Day in London on November 16, 2026, to discuss MTAP/CDKN2A and KRAS pancreatic cancer development strategies.
18 Articles
18 Articles
Morgan County Citizen
inovio.comINOVIO to Participate in Upcoming Investor Conferences
PLYMOUTH MEETING, Pa., Sept. 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in…
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to treat and prevent severe allergic reactions, today announced that Donn Casale, President and CEO, will…
North Bay Nipissing
Financial PostProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
CAMBRIDGE, Mass, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming September 2026 conferences…
BridgeBio to Participate in September Investor Conferences
PALO ALTO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate…
Q32 Bio to Participate in Upcoming September Investor Conferences
WALTHAM, Mass., Sept. 1, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced that management will participate…
Coverage Details
Bias Distribution
- 63% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
